reports
- Sean Conroy
Suda Pharmaceuticals - A potentially transformational acquisition
SUDA recently announced that it will be licensing an invariant natural killer T (iNKT) cell therapy platform from Imperial College London that can be used in conjunction with chimeric antigen receptors (CARs) to target blood cancers. Specific financial terms are undisclosed but include an upfront fee, annual maintenance fees, milestones and a single-digit royalty. There are a number of potential benefits of CAR-iNKT, including the prospect of being an allogeneic ‘off-the-shelf’ therapy, signific...
- Sean Conroy
Suda Pharmaceuticals - Half-year update
SUDA continues to make progress with anagrelide. In an animal model, SUDA was able to show that an oral spray formulation had 43% higher bioavailability over a capsule form while only showing a 28% increase in exposure of the cardiostimulatory metabolite. This provides evidence that this formulation may allow for a lower dose of anagrelide, maintaining efficacy, but with reduced cardiotoxicity, a significant issue with the capsule formulation. In February, the company announced that it has contr...
- Sean Conroy
Suda Pharmaceuticals - A TGA approval and a capital raise
SUDA has had a busy couple of months, announcing approval for ZolpiMist in Australia by the Therapeutics Goods Administration (TGA) in July, as well as raising A$4.1m in additional capital. The TGA approval demonstrates SUDA’s compliance with Good Manufacturing Practice (GMP) as well as an ability to obtain regulatory approvals. This approval will assist SUDA’s current partners in their submissions in the territories for which they are responsible.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.